Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: Rationale, and evidence for advantages over existing systems

CNS Drugs

Volumn 27, Issue 12, 2013, Pages 1007-1019

  Shahab, Lion ^a   Brose, Leonie S ^b   West, Robert ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON NANOTUBE; ELECTRONIC CIGARETTE; NICOTINE; NICOTINE CANNON; NICOTINE FILM; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; NICOTINE POUCH; NICOTINE SPRAY; NICOTINE STRAW; NICOTINE STRIP; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIZZINESS; DRUG ABUSE; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HEARTBURN; HICCUP; HUMAN; HYPERSALIVATION; INHALER; JAW PAIN; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MOUTH DISCOMFORT; MOUTH PAIN; NAUSEA; NEBULIZER; NICOTINE REPLACEMENT THERAPY; NONHUMAN; NOSE IRRITATION; ORAL SPRAY; PRIORITY JOURNAL; RASH; RISK REDUCTION; SKIN MANIFESTATION; SLEEP DISORDER; SMOKING CESSATION; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOBACCO DEPENDENCE; TONGUE IRRITATION; VIVID DREAM;

DRUG DELIVERY SYSTEMS; HARM REDUCTION; HUMANS; NICOTINE; SMOKING; SMOKING CESSATION;

EID: 84890460864     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0116-4     Document Type: Article

References (122)

1. Shafey O, Eriksen M, Ross H, Mackay J. The tobacco atlas. 3rd ed. Atlanta: American Cancer Society; 2009.
2. Waldum HL, Nilsen OG, Nilsen T, Rorvik H, Syversen V, Sanvik AK, et al. Long-term effects of inhaled nicotine. Life Sci. 1996;58:1339-46.
3. Sumner W. Estimating the health consequences of replacing cigarettes with nicotine inhalers. Tob Control. 2003;12:124-32.
4. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993;33:23-9.
5. Jarvis MJ. Why people smoke. BMJ. 2004;328:277-9.
6. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron. 1998;21:467-76.
7. Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res. 2000;2:19-37.
8. Centers for Disease Control and Prevention. The health consequences of smoking: nicotine addiction. A report of the surgeon general. Rockville: US Department of Health and Human Services; 1988.
9. Royal College of Physicians. Nicotine addiction in Britain. A report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians of London; 2000.
10. West R. The multiple facets of cigarette addiction and what they mean for encouraging and helping smokers to stop. COPD. 2009;6:277-83.
11. International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. In: IARC monographs on the evaluation of carcinogenic risks to humans, vol 83. Lyon: IARC; 2004. p. 973-991.
12. Press release: UK moves towards safe and effective electronic cigarettes and other nicotine-containing products. MHRA website. http://www.mhra.gov.uk/ NewsCentre/Pressreleases/CON286855.
13. Johnston L. Tobacco smoking and nicotine. Lancet. 1942;240:742.
14. Herxheimer A, Griffith R, Hamilton B, Wakefield M. Circulatory effects of nicotine aerosol inhalations and cigarette smoking in man. Lancet. 1967;290:754-5.
15. Ferno O. Conversation with Ove Ferno. Addiction. 1994;89:1215-26.
16. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med. 2011;365:1193-200.
17. Mees HL, Keutzer CS, Lichtenstein E. Modification of smoking behavior: a review. Psychol Bull. 1968;70:520-33.
18. Ferno O, Lichtnec SJ, Lundgren CE. Substitute for tobacco smoking. Psychopharmacologia. 1973;31:201-4.
19. Brantmark B, Ohlin P, Westling H. Nicotine-containing chewing gum as an anti-smoking aid. Psychopharmacologia. 1973;31:191-200.
20. Jarvik M. Conversation with Murray Jarvik. Addiction. 2001;96:1241-52.
21. Buchhalter AR, Fant RV, Henningfield JE. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs. 2008;68:1067-88.
22. Rose JE, Herskovic JE, Trilling Y, Jarvik ME. Transdermal nicotine reduces cigarette craving and nicotine preference. Clin Pharmacol Ther. 1985;38:450-6.
23. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
24. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med. 1999;159:2033-8.
25. Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res. 1999;1:169-74.
26. Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet. 1992;340:324-9.
27. Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology (Berl). 1993;111:271-7.
28. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. 1995;24:41-7.
29. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66:1253-62.
30. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;CD000146.
31. Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. Drug Alcohol Rev. 2008;27:529-47.
32. Comparison of four methods of smoking withdrawal in patients with smoking related diseases. Report by a subcommittee of the Research Committee of the British Thoracic Society. Br Med J (Clin Res Ed). 1983;286:595-7.
33. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 2002;288:1260-4.
34. Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev. 2006;25:59-71.
35. Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority. Thorax. 1998;53(Suppl 5 Pt 2):S1-38.
36. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6:1-245.
37. Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet. 1999;354:210-5.
38. Akehurst R, Piercy J. Cost-effectiveness of the use of transdermal Nicorette patches relative to GP counselling and nicotine gum in the prevention of smoking related diseases. Br J Med Econ. 1994;7:115-22.
39. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997;278:1759-66.
40. Appleby J, Devlin N, Parkin D. NICE's cost effectiveness threshold. BMJ. 2007;335:358-9.
41. NICE. Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. In: NICE public health guidance 10. London: National Institute for Health and Clinical Excellence; 2008.
42. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000;55:987-99.
43. USDHHS. Clinical practical guidelines. In: Treating tobacco use and dependence - 2008 update. Rockville: US Department of Health and Human Services P.H.S.; 2008.
44. Hughes JR, Shiffman S, Callas P, Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control. 2003;12:21-7.
45. Raw M, Regan S, Rigotti NA, McNeill A. A survey of tobacco dependence treatment services in 36 countries. Addiction. 2009;104:279-87.
46. WHO Tobacco Free Initiative. Policy recommendations for smoking cessation and treatment of tobacco dependence. Geneva: WHO; 2003.
47. Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology (Berl). 1984;83:82-7.
48. West R, Jarvis MJ, Russell MA, Carruthers ME, Feyerabend C. Effect of nicotine replacement on the cigarette withdrawal syndrome. Br J Addict. 1984;79:215-9.
49. Jarvis MJ, Raw M, Russell MA, Feyerabend C. Randomised controlled trial of nicotine chewing-gum. Br Med J (Clin Res Ed). 1982;285:537-40.
50. West R. The 'nicotine replacement paradox' in smoking cessation: how does nicotine gum really work? Br J Addict. 1992;87:165-7.
51. Shiffman S, Fant RV, Buchhalter AR, Gitchell JG, Henningfield JE. Nicotine delivery systems. Expert Opin Drug Deliv. 2005;2:563-77.
52. Esterlis I, Mitsis EM, Batis JC, Bois F, Picciotto MR, Stiklus SM, et al. Brain beta2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. Int J Neuropsychopharmacol. 2011;14:389-98.
53. West R, Shiffman S. Fast facts: smoking cessation. 2nd ed. Oxford: Health Press; 2007.
54. Beard E, McNeill A, Aveyard P, Fidler J, Michie S, West R. Association between use of nicotine replacement therapy for harm reduction and smoking cessation: a prospective study of English smokers. Tob Control. 2013;22:118-22.
55. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009;338:b1024.
56. Agboola S, McNeill A, Coleman T, Leonardi BJ. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction. 2010;105:1362-80.
57. Raw M, McNeill A, West R, Arnott D. Guidance for health professionals on changes in the licensing arrangements for nicotine replacement therapy. London: ASH; 2005.
58. Henningfield JE, Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J. 1998;53(suppl):75-114.
59. Schneider NG, Koury MA, Cortner C, Olmstead RE, Hartman N, Kleinman L, et al. Preferences among four combination nicotine treatments. Psychopharmacology (Berl). 2006;187:476-85.
60. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med. 2004;140:426-33.
61. West R, DiMarino ME, Gitchell J, McNeill A. Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control. 2005;14:166-71.
62. Kotz D, Fidler JA, West R. Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications? Nicotine Tob Res. 2011;13:793-9.
63. Pomerleau OF. Nicotine and the central nervous system: biobehavioral effects of cigarette smoking. Am J Med. 1992;93:2S-7S.
64. Russell MA, Sutton SR, Iyer R, Feyerabend C, Vesey CJ. Long-term switching to low-tar low-nicotine cigarettes. Br J Addict. 1982;77:145-58.
65. McRobbie H, Raw M, Chan S. Research priorities for Article 14 - demand reduction measures concerning tobacco dependence and cessation. Nicotine Tob Res. 2013;15:805-16.
66. DeVeaugh-Geiss AM, Chen LH, Kotler ML, Ramsay LR, Durcan MJ. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. Clin Ther. 2010;32:1140-8.
67. Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG. Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology (Berl). 2006;184:637-44.
68. Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. 1999;13:238-46.
69. Chen L-L, Inventors. United States Patent Application Publication (US 20011/0110880 A1). Nicotine Lozenge compositions (Application number: 12/990,049, filed 30 Apr 2009). 2011.
70. MHRA. Public assessment report. Nicabate Mini 1.5 mg compressed lozenges and Nicabate Mini 4 mg compressed lozenges. http://www.mhra.gov.uk/home/groups/ pl-a/documents/websiteresources/con020733.pdf. Accessed online June 2013.
71. Shahab L, McEwen A, West R. Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: a randomised crossover trial. Psychopharmacology (Berl). 2011;216:187-96.
72. Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M, et al. Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction. 2005;100:1720-30.
73. Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, et al. Rapid absorption of nicotine from new nicotine gum formulations. Pharmacol Biochem Behav. 2009;91:380-4.
74. McEwen A, West R, Gaiger M. Nicotine absorption from seven current nicotine replacement products and a new wide-bore nicotine delivery device. J Smok Cessat. 2008;3:117-23.
75. Bolliger CT, van Biljon X, Axelsson A. A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy. Respiration. 2007;74:196-201.
76. Kraiczi H, Hansson A, Perfekt R. Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. Nicotine Tob Res. 2011;13:1176-82.
77. McRobbie H, Thornley S, Bullen C, Lin RB, Senior H, Laugesen M, et al. A randomized trial of the effects of two novel nicotine replacement therapies on tobacco withdrawal symptoms and user satisfaction. Addiction. 2010;105:1290-8.
78. Hansson A, Hajek P, Perfekt R, Kraiczi H. Effects of nicotine mouth spray on urges to smoke, a randomised clinical trial. BMJ Open. 2012;2:e001618.
79. Tonnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J. 2012;40:548-54.
80. Thornley S, McRobbie H, Lin RB, Bullen C, Hajek P, Laugesen M, et al. A single-blind, randomized, crossover trial of the effects of a nicotine pouch on the relief of tobacco withdrawal symptoms and user satisfaction. Nicotine Tob Res. 2009;11:715-21.
81. Walker N, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, et al. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial. Addiction. 2011;106:1176-85.
82. Caldwell B, Burgess C, Crane J. Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Nicotine Tob Res. 2010;12:179-83.
83. GlaxoSmithKline. Clinical Trial: Nicotine Mouth Film for Craving Relief (NCT01702532). 2013. http://www.clinicaltrials.gov/ct2/show/NCT01702532?term= NCT01702532&rank=1.
84. Cilurzo F, Cupone IE, Minghetti P, Buratti S, Selmin F, Gennari CG, et al. Nicotine fast dissolving films made of maltodextrins: a feasibility study. AAPS PharmSciTech. 2010;11:1511-7.
85. MHRA. Public assessment report: Nicabate mint 2.5 mg orodispersable film (PL 00079/0640). http://www.mhra.gov.uk/home/groups/par/documents/ websiteresources/con123160.pdf. Accessed online June 2013.
86. Valenta C, Auner BG. The use of polymers for dermal and transdermal delivery. Eur J Pharm Biopharm. 2004;58:279-89.
87. Pichayakorn W, Suksaeree J, Boonme P, Amnuaikit T, Taweepreda W, Ritthidej GC. Deproteinized natural rubber film forming polymeric solutions for nicotine transdermal delivery. Pharm Dev Technol. 2013;18:1111-21.
88. Rao S, Song Y, Peddie F, Evans AM. A novel tri-layered buccal mucoadhesive patch for drug delivery: assessment of nicotine delivery. J Pharm Pharmacol. 2011;63:794-9.
89. Strasinger CL, Scheff NN, Wu J, Hinds BJ, Stinchcomb AL. Carbon nanotube membranes for use in the transdermal treatment of nicotine addiction and opioid withdrawal symptoms. Subst Abuse. 2009;3:31-9.
90. Paudel KS, Wu J, Hinds BJ, Stinchcomb AL. Programmable transdermal delivery of nicotine in hairless guinea pigs using carbon nanotube membrane pumps. J Pharm Sci. 2012;101:3823-32.
91. Wu J, Paudel KS, Strasinger C, Hammell D, Stinchcomb AL, Hinds BJ. Programmable transdermal drug delivery of nicotine using carbon nanotube membranes. Proc Natl Acad Sci USA. 2010;107:11698-702.
92. D'Orlando KJ, Fox BS. Tolerability and pharmacokinetics of single and repeated doses of nicotine with the straw, a novel nicotine replacement product. Nicotine Tob Res. 2004;6:63-70.
93. Westman EC, Tomlin KF, Perkins CE, Rose JE. Oral nicotine solution for smoking cessation: a pilot tolerability study. Nicotine Tob Res. 2001;3:391-6.
94. Henningfield JE, Radzius A, Cooper TM, Clayton RR. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA. 1990;264:1560-4.
95. Islam N, Rahman S. Improved treatment of nicotine addiction and emerging pulmonary drug delivery. Drug Discov Ther. 2012;6:123-32.
96. Caldwell B, Sumner W, Crane J. A systematic review of nicotine by inhalation: is there a role for the inhaled route? Nicotine Tob Res. 2012;14:1127-39.
97. Lux JE, Frecker RC. Subjective responses to inhaled and intravenous injected nicotine. Clin Pharmacol Ther. 1988;43:186.
98. Burch SG, Erbland ML, Gann LP, Hiller FC. Plasma nicotine levels after inhalation of aerosolized nicotine. Am Rev Respir Dis. 1989;140:955-7.
99. Andrus PG, Rhem R, Rosenfeld J, Dolovich MB. Nicotine microaerosol inhaler. Can Respir J. 1999;6:509-12.
100. Caldwell B, Dickson S, Burgess C, Siebers R, Mala S, Parkes A, et al. A pilot study of nicotine delivery to smokers from a metered-dose inhaler. Nicotine Tob Res. 2009;11:342-7.
101. Farr SJ, Warren SJ, Lloyd P, Okikawa JK, Schuster JA, Rowe AM, et al. Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler. Int J Pharm. 2000;198:63-70.
102. Rose JE, Turner JE, Murugesan T, Behm FM, Laugesen M. Pulmonary delivery of nicotine pyruvate: sensory and pharmacokinetic characteristics. Exp Clin Psychopharmacol. 2010;18:385-94.
103. Wollscheid KA, Kremzner ME. Electronic cigarettes: safety concerns and regulatory issues. Am J Health Syst Pharm. 2009;66:1740-2.
104. Goniewicz ML, Kuma T, Gawron M, Knysak J, Kosmider L. Nicotine levels in electronic cigarettes. Nicotine Tob Res. 2013;15:158-66.
105. Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control. 2010;19:98-103.
106. Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev. 2010;19:1945-53.
107. Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res. 2013;15:267-70.
108. Dawkins L, Turner J, Hasna S, Soar K. The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition. Addict Behav. 2012;37:970-3.
109. Bullen C, Williman J, Howe C, Laugesen M, McRobbie H, Parag V, et al. Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation. BMC Public Health. 2013;13:210.
110. Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. Efficiency and safety of an electronic cigarette (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013;8:e66317.
111. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet (In press).
112. Polosa R, Morjaria JB, Caponnetto P, Campagna D, Russo C, Alamo A, et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Intern Emerg Med. 2013. doi: 10.1007/s11739-013-0977-z.
113. Caponnetto P, Auditore R, Russo C, Cappello GC, Polosa R. Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health. 2013;10:446-61.
114. Trehy ML, Ye W, Hadwiger ME, Moore TW, Allgire JF, Woodruff JT, et al. Analysis of electronic cigarette cartridges, refill solutions, and smoke for nicotine and nicotine related impurities. J Liquid Chromatogr Relat Technol. 2011;34:1442-58.
115. Hajek P. Withdrawal-oriented therapy for smokers. Br J Addict. 1989;84:591-8.
116. Hurt RD, Dale LC, McClain FL, Eberman KM, Offord KP, Bruce BK, et al. A comprehensive model for the treatment of nicotine dependence in a medical setting. Med Clin North Am. 1992;76:495-514.
117. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012;10:CD008286.
118. Sutherland G. Evidence for counselling effectiveness for smoking cessation. J Clin Psychiatry Monogr. 2003;18:22-34.
119. Shahab L, Fidler J. Tobacco-related disorders. In: Sturmey P, Hersen M, editors. Handbook of evidence-based practice in clinical psychology: adult disorders, vol. II. New York: Wiley; 2012. pp. 167-96.
120. McEwen A, Hajek P, McRobbie H, West R. Manual of smoking cessation. Oxford: Blackwell Publishing; 2006.
121. Shahab L. Cost-effectiveness of pharmacotherapy for smoking cessation (NCSCT Briefing: 7). In: McEwen A, editor. NHS Centre for Smoking Cessation and Training Briefings. London: NCSCT; 2011.
122. Fidler JA, Shahab L, West O, Jarvis MJ, McEwen A, Stapleton JA, et al. 'The smoking toolkit study': a national study of smoking and smoking cessation in England. BMC Public Health. 2011;11:479.